Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: the example of joint disease

Fig. 6

Secretome effects on inflamed macrophages and chondrocytes. a Macrophages (CTRL) were treated for 24 h with inflammatory cytokines without (IFNγ/TNFα) and with secretome (IT+SEC) or IFNγ-primed secretome (IT+PSEC). Untreated cells were used as control (CTRL). CD86 (M1 phenotype) and CD163 (M2 phenotype) were detected by flow cytometry. Values on the y-axis are intended as ratios obtained comparing CD86 and CD163 median fluorescence intensities subtracted of their unstained control values and arbitrarily set as 1 for CTRL. Increased CD86/CD163 ratio is an indication of M1 phenotype polarization. b Chondrocytes (CTRL) were treated with inflammatory cytokine without (IL-1β) and with secretome (I+SEC) or IFNγ-primed secretome (I+PSEC). VCAM1 was detected by flow cytometry. Values on the y-axis show the percentage of VCAM1-positive cells. N = 3, *p < 0.05, **p < 0.01; ns, not significant

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512